EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey

Aleksandra Zurowska iD, Magdalena Drozynska-Duklas iD, Rezan Topaloglu iD, Antonia Bouts iD, Olivia Boyer iD, Mohan Shenoy iD, Marina Vivarelli iD, ESPN Glomerulonephritis Working Group

Pediatric Nephrology · 2023-09 · 38 (9) · 3035-3042

DOI: 10.1007/s00467-023-05913-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Nephrology, online erschienen am 04.04.2023. Verfasst von Aleksandra Zurowska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdańsk, ul. Debinki 7, 80-952, Gdańsk, Poland. aleksandra.zurowska@gumed…. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Agammaglobulinemia. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is paucity of information on rituximab-associated hypogammaglobulinemia (HGG) and its potential infectious consequences in children treated for idiopathic nephrotic syndrome (INS).

Methods

A survey was distributed by the European Society Pediatric Nephrology to its members. It addressed the screening and management practices of pediatric nephrology units for recognizing and treating RTX-associated HGG and its morbidity and mortality. Eighty-four centers which had treated an overall 1328 INS children with RTX responded.

Results

The majority of centers administered several courses of RTX and continued concomitant immunosuppressive therapy. Sixty-five percent of centers routinely screened children for HGG prior to RTX infusion, 59% during, and 52% following RTX treatment. Forty-seven percent had observed HGG prior to RTX administration, 61% during and 47% >9 months following treatment in 121, 210, and 128 subjects respectively. Thirty-three severe infections were reported among the cohort of 1328 RTX-treated subjects, of whom 3 children died. HGG had been recognized in 30/33 (80%) of them.

Conclusions

HGG in steroid-dependent/frequently relapsing nephrotic syndrome (SDNS/FRNS) children is probably multifactorial and can be observed prior to RTX administration in children with SDNS/FRNS. Persistent HGG lasting >9 months from RTX infusion is not uncommon and may increase the risk of severe infections in this cohort. We advocate for the obligatory screening for HGG in children with SDNS/FRNS prior to, during, and following RTX treatment. Further research is necessary to identify risk factors for developing both HGG and severe infections before recommendations are made for its optimal management. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephrotic SyndromeAgammaglobulinemiaChildHumansRituximabImmunosuppressive AgentsRecurrenceTreatment Outcome

Stichwörter der Autor:innen

ChildrenHypogammaglobulinemiaNephrotic syndromeRituximab

Substanzen

RituximabImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdańsk, ul. Debinki 7, 80-952, Gdańsk, Poland. aleksandra.zurowska@gumed.edu.pl.
  • Centre for Rare Diseases, Medical University of Gdańsk, Gdańsk, Poland. aleksandra.zurowska@gumed.edu.pl.
  • Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdańsk, ul. Debinki 7, 80-952, Gdańsk, Poland.
  • Department of Pediatric Nephrology, Hacettepe University School of Medicine Hacettepe University, Ankara, Turkey.
  • Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Department of Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, Necker Hospital, Paris, France.

ORCID-Profile: Aleksandra Zurowska, Magdalena Drozynska-Duklas, Rezan Topaloglu, Antonia Bouts, Olivia Boyer, Mohan Shenoy, Marina Vivarelli

Zitieren

APA

Zurowska, A., Drozynska-Duklas, M., Topaloglu, R., Bouts, A., Boyer, O., Shenoy, M., Vivarelli, M., & ESPN Glomerulonephritis Working Group (2023). Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatric Nephrology, 38(9), 3035-3042. https://doi.org/10.1007/s00467-023-05913-1

Vancouver

Zurowska A, Drozynska-Duklas M, Topaloglu R, Bouts A, Boyer O, Shenoy M, et al. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatric Nephrology. 2023;38(9):3035-3042. doi:10.1007/s00467-023-05913-1

BibTeX
@article{Zurowska2023,
  author = {Zurowska, Aleksandra and Drozynska-Duklas, Magdalena and Topaloglu, Rezan and Bouts, Antonia and Boyer, Olivia and Shenoy, Mohan and Vivarelli, Marina and ESPN Glomerulonephritis Working Group, ESPN Glomerulonephritis Working Group},
  title = {Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey},
  journal = {Pediatric Nephrology},
  year = {2023},
  volume = {38},
  number = {9},
  pages = {3035--3042},
  doi = {10.1007/s00467-023-05913-1}
}
Kostenlos starten →